

Editor's Note

Epidemiol. Infect. **104** (1990), 143–9

Following publication of the paper by Dahl-Hansen and colleagues (*Epidemiology and Infection* 1990; **104**: 143–9) we received a letter from Dr David West of Merck Sharp & Dohme Research Laboratories pointing out that the batch of yeast-derived hepatitis B vaccine made by Merck Sharp & Dohme which was used in the trial differed from the currently available vaccine. This has been modified to enhance its purity and immunogenicity [1–3]. In view of the importance of hepatitis B vaccination, we decided that we should draw the attention of readers to this modification.

1. Gerety RJ, Ellis RW, Zajac BA, et al. *JAMA* 1988; **259**: 2403–4.
2. West DJ, Zajac BA, Ellis RW, et al. *Infektionsklin* 1988; **1**: 3–7.
3. West DJ. *Am J Infect Control* 1989; **17**: 172–80.